147 related articles for article (PubMed ID: 20117197)
41. Amorphous Solid Dispersion of Meloxicam Enhanced Oral Absorption in Rats With Impaired Gastric Motility.
Suzuki H; Yakushiji K; Matsunaga S; Yamauchi Y; Seto Y; Sato H; Onoue S
J Pharm Sci; 2018 Jan; 107(1):446-452. PubMed ID: 28551427
[TBL] [Abstract][Full Text] [Related]
42. Population pharmacokinetic modelling and simulation of single and multiple dose administration of meloxicam in cats.
Lehr T; Narbe R; Jöns O; Kloft C; Staab A
J Vet Pharmacol Ther; 2010 Jun; 33(3):277-86. PubMed ID: 20557445
[TBL] [Abstract][Full Text] [Related]
43. Nonsteroidal antiinflammatory drugs: a review.
Curry SL; Cogar SM; Cook JL
J Am Anim Hosp Assoc; 2005; 41(5):298-309. PubMed ID: 16141181
[TBL] [Abstract][Full Text] [Related]
44. Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of oxicam NSAIDs.
Suarez-Kurtz G
Pharmacogenet Genomics; 2014 Aug; 24(8):406-7. PubMed ID: 25003537
[No Abstract] [Full Text] [Related]
45. The effect of the composition of a fixed dose combination on bioequivalence results.
Šalandová J; Franc A; Hofmann J; Dumicic A; Kukačková L; Červená T; Beránek J; Srbek J; Repický A; Vladovičová B; Vetchý D
Int J Pharm; 2018 Jul; 546(1-2):235-246. PubMed ID: 29758343
[TBL] [Abstract][Full Text] [Related]
46. Formulation optimization of meloxicam sodium gel using response surface methodology.
Chang JS; Huang YB; Hou SS; Wang RJ; Wu PC; Tsai YH
Int J Pharm; 2007 Jun; 338(1-2):48-54. PubMed ID: 17360134
[TBL] [Abstract][Full Text] [Related]
47. Gastrointestinal mucosal injury following repeated daily oral administration of conventional formulations of indometacin and other non-steroidal anti-inflammatory drugs to pigs: a model for human gastrointestinal disease.
Rainsford KD; Stetsko PI; Sirko SP; Debski S
J Pharm Pharmacol; 2003 May; 55(5):661-8. PubMed ID: 12831509
[TBL] [Abstract][Full Text] [Related]
48. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
49. Response to Suarez-Kurtz's comments on strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals.
Lee HI; Bae JW; Choi CI; Lee YJ; Byeon JY; Jang CG; Lee SY
Pharmacogenet Genomics; 2014 Aug; 24(8):407-8. PubMed ID: 25003538
[No Abstract] [Full Text] [Related]
50. Rheological behavior of gels and meloxicam release.
Ruiz Martinez MA; López-Viota Gallardo J; de Benavides MM; de Dios García López-Duran J; Gallardo Lara V
Int J Pharm; 2007 Mar; 333(1-2):17-23. PubMed ID: 17056213
[TBL] [Abstract][Full Text] [Related]
51. Particle engineering/different film approaches for earlier absorption of meloxicam.
Farid M; El-Setouhy DA; El-Nabarawi MA; El-Bayomi T
Drug Deliv; 2016 Sep; 23(7):2309-2317. PubMed ID: 25431841
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics of meloxicam in rabbits after single and repeat oral dosing.
Turner PV; Chen HC; Taylor WM
Comp Med; 2006 Feb; 56(1):63-7. PubMed ID: 16521861
[TBL] [Abstract][Full Text] [Related]
53. Tablet formulation studies on nimesulide and meloxicam-cyclodextrin binary systems.
Nalluri BN; Chowdary KP; Murthy KV; Becket G; Crooks PA
AAPS PharmSciTech; 2007 May; 8(2):Article 36. PubMed ID: 17622114
[TBL] [Abstract][Full Text] [Related]
54. The effect of meloxicam/ethanolamine salt formation on percutaneous absorption of meloxicam.
Ki HM; Choi HK
Arch Pharm Res; 2007 Feb; 30(2):215-21. PubMed ID: 17366744
[TBL] [Abstract][Full Text] [Related]
55. Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam.
Ambrus R; Kocbek P; Kristl J; Sibanc R; Rajkó R; Szabó-Révész P
Int J Pharm; 2009 Nov; 381(2):153-9. PubMed ID: 19616609
[TBL] [Abstract][Full Text] [Related]
56. Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation.
Pallagi E; Ambrus R; Szabó-Révész P; Csóka I
Int J Pharm; 2015 Aug; 491(1-2):384-92. PubMed ID: 26134895
[TBL] [Abstract][Full Text] [Related]
57. [Pharmacodynamic and pharmacokinetic aspects of the non-inflammatory non-steroidal agent meloxicam in dogs].
Poulsen Nautrup B; Hörstermann D
Dtsch Tierarztl Wochenschr; 1999 Mar; 106(3):94-100. PubMed ID: 10220944
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects.
Schmid J; Busch U; Heinzel G; Bozler G; Kaschke S; Kummer M
Drug Metab Dispos; 1995 Nov; 23(11):1206-13. PubMed ID: 8591720
[TBL] [Abstract][Full Text] [Related]
59. Rationale for faster oral delivery to overcome the pathophysiology associated with dental pain--biopharmaceutic and pharmacokinetic challenges.
Srinivas NR
Eur J Drug Metab Pharmacokinet; 2009; 34(1):7-10. PubMed ID: 19462922
[TBL] [Abstract][Full Text] [Related]
60. In vitro and in vivo characterization of meloxicam nanoparticles designed for nasal administration.
Kürti L; Gáspár R; Márki Á; Kápolna E; Bocsik A; Veszelka S; Bartos C; Ambrus R; Vastag M; Deli MA; Szabó-Révész P
Eur J Pharm Sci; 2013 Sep; 50(1):86-92. PubMed ID: 23542493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
